Gunilla Osswald

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

L. Lannfelt, M. Ingelsson, C. Möller, 2021, Neurobiology of Disease.

An Open Study of Clomethiazole in Patients with Acute Cerebral Infarction

N. Wahlgren, Gunilla Osswald, T. Strand, 1998, Cerebrovascular Diseases.

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

L. Lannfelt, H. Basun, A. Satlin, 2016, Alzheimer's Research & Therapy.

The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.

L. Lannfelt, A. Satlin, C. Möller, 2014, Journal of Alzheimer's disease : JAD.

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

L. Lannfelt, C. Möller, F. Eriksson, 2022, Neurotherapeutics.

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

L. Lannfelt, H. Basun, A. Satlin, 2016, Alzheimer's Research & Therapy.

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

L. Lannfelt, H. Basun, A. Satlin, 2014, Alzheimer's Research & Therapy.

How Partnership Should Work to Bring Innovative Medicines to Patients.

A. Maroney, Gunilla Osswald, Marco Giorgetti, 2020, Drug discovery today.

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

Gavin J. Cook, M. Gallagher, M. Carrillo, 2023, The Journal of Prevention of Alzheimer's Disease.